Tag results:

T cells

Liver-Specific Overexpression of Gab2 Accelerates Hepatocellular Carcinoma Progression by Activating Immunosuppression of Myeloid-Derived Suppressor Cells

[Oncogene] Liver-specific overexpression of GRB2-associated-binding protein 2 (Gab2) mice accelerated hepatoma progression possibly through activating IL-6-initiated the activation of myeloid-derived suppressor cells.

Ubiquitin-Like Protein 3 (UBL3) Is Required for MARCH Ubiquitination of Major Histocompatibility Complex Class II and CD86

[Nature Communications] Researchers showed, using a genome-wide CRISPR knockout screen, that UBL3 was a necessary component of ubiquitination-mediated trafficking of major histocompatibility complex class II and CD86 in mice and in humans.

LPA Suppresses T Cell Function by Altering the Cytoskeleton and Disrupting Immune Synapse Formation

[Proceedings of the National Academy of Sciences of the United States of America] The authors suggested that targeting lysophosphatidic acid (LPA) signaling in chronic inflammatory conditions may have rescued T cell function and promoted antiviral and antitumor immunity.

PD-1 Cooperates with AIRE-Mediated Tolerance to Prevent Lethal Autoimmune Disease

[Proceedings of the National Academy of Sciences of the United States of America] Using a range of mouse genetic models, researchers uncovered a critical tolerogenic axis between the autoimmune regulator, AIRE, and the immune checkpoint molecule, PD-1.

Binding of LAG-3 to Stable Peptide-MHC Class II Limits T Cell Function and Suppresses Autoimmunity and Anti-Cancer Immunity

[Immunity] Researchers investigated the relative contribution of potential ligands, stable peptide-MHC class II complexes and fibrinogen-like protein 1, to lymphocyte activation gene-3 (LAG-3) activity in vitro and in vivo.

CCR2/CCR5 Inhibitor Permits the Radiation-Induced Effector T Cell Infiltration in Pancreatic Adenocarcinoma

[Journal of Experimental Medicine] Using PDAC mouse models, scientists demonstrated that radiation therapy followed by anti-PD-1 antibody and prolonged treatment with CCR2/5i conferred better antitumor efficacy than other combination treatments tested.